Collegium Pharmaceutical Inc. Registered Shares DL -,001
- BID
31.6
- ASK
31.8
- 1,197 Units563 Units
- 07/21, 16:36:21 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
16.54%
Market Cap
-
P/E Ratio
26.69
Dividend Yield
0.00 %
Earnings per Share
1.54 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 31.6 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 04:31:21 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 31.6 | 30.6 |
| PREV. DAY'S PRICE | 31 | (07/20) |
| CHANGE DAY BEFORE | +0.60 | 1.94 % |
| 52 WEEK HIGH / LOW | 42.2 (12/22) | 25 (08/07) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | 1.20 | 1.72 | 1.54 | 6.83 | 6.62 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | - | - |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | 23.80 | 15.43 | 26.69 | 4.63 | 4.78 |
PRICE - BOOK RATIO | 5.02 | 3.94 | 4.87 | - | - |
PRICE - SALES RATIO | 2.27 | 1.83 | 2.35 | - | - |
PRICE - CASH FLOW RATIO | 4.68 | 5.65 | 5.58 | - | - |
Master Data
| WKN | A14SUV |
| ISIN | US19459J1043 |
| SYMBOL | 354 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | COLLEGIUM PHARMAC.DL-,001 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 1.97 % | 6.90 % | 6.90 % | -23.27 % | 16.54 % | 62.30 % | 50.49 % | -25.12 % |
| HIGH | 32.80 | 33.40 | 33.40 | 41.20 | 42.20 | 42.20 | 42.20 | 42.00 |
| LOW | 29.80 | 28.60 | 25.80 | 25.80 | 25.00 | 19.20 | 13.20 | 25.80 |
Dividende
pro Aktie
COLLEGIUM PHARMAC.DL-,001 does not deliver dividend information
Company profile
Collegium Pharmaceutical, Inc. is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. The firm has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.